Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 12—December 2015

Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea

Wan Beom Park1, Ranawaka A.P.M. Perera1, Pyoeng Gyun Choe, Eric H.Y. Lau, Seong Jin Choi, June Young Chun, Hong Sang Oh, Kyoung-Ho Song, Ji Hwan Bang, Eu Suk Kim, Hong Bin Kim, Sang Won Park, Nam Joong Kim, Leo Lit Man Poon, Ghazi KayaliComments to Author , and Myoung-don OhComments to Author 
Author affiliations: Seoul National University College of Medicine, Seoul, South Korea (W.B. Park, P.G. Choe, S.J. Choi, J.Y. Chun, H.S. Oh, K.-H. Song, J.H. Bang, E.S. Kim, H.B. Kim, S.W. Park, N.J. Kim, M.-d. Oh); The University of Hong Kong, Pokfulam, Hong Kong, China (R.A.P.M. Perera, E.H.Y. Lau, L.L.M. Poon); Hong Kong University–Pasteur Research Pole, Pokfulam (M. Peiris)

Main Article

Table 1

Associations and p values for different clinical factors with time from illness onset to commencement of log phase of antibody response in PRNT50 and S1-ELISA*

Clinical factors Acceleration factor of time from illness onset to log phase of antibody response
PRNT50 titer p value S1-ELISA OD ratio‡ p value
Severe disease 1.61 <0.001 1.19 0.21
Male sex† 0.90 0.52 0.90 0.48
Age >60 y† 0.95 0.73 1.08 0.60
Incubation period, d† 0.97 0.06 0.95 <0.001
Use of corticosteroid† 1.19 0.33 1.14 0.47
Use of antiviral drugs† 1.07 0.61 0.76 0.03
Concomitant conditions† 1.08 0.57 1.15 0.30

*Accelerated failure time models were used; acceleration factor >1 means a longer interval to commencement of antibody response. OD, optical density; PRNT50, 50% endpoint plaque reduction neutralization test.
†Effects were adjusted for severity.
‡Increase over S1-ELISA OD >0.8..

Main Article

1These authors contributed equally to this article.

Page created: November 17, 2015
Page updated: November 17, 2015
Page reviewed: November 17, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.